Date lodged: 11 December 2018
To ask the Scottish Government what its response is to the call by Breast Cancer Now for Perjeta to be made routinely available for people with secondary breast cancer.
Answered by: Jeane Freeman 7 January 2019
On 10 December the Scottish Medicines Consortium announced that they had recommended Perjeta for use in NHS Scotland for the neoadjuvant treatment of breast cancer. A second indication, for the treatment of metastatic (secondary) breast cancer was considered at the December meeting of the SMC and their decision will be published in January.